GENEART Awarded European Patent for Tested HIV Vaccines
News Apr 09, 2008
The GENEART AG announces the award of the patent EP 1240333 titled "Das Genom des HIV-1 Intersubtyps (C/B') und seine Anwendungen" ("The Genome of HIV-1 Intersubtype (C/B') and Use Thereof") by the European Patent Office.
The above-mentioned patent protects the use of certain custom-designed HIV gene sequences for the development of therapeutics or vaccines in the following countries: Austria, Belgium, France, Germany, Great Britain, Italy, Luxembourg, the Netherlands, Spain and Switzerland. The US American patent of the patent family was already assigned in February.
The patent describes gene sequences, which have already been successfully tested as HIV vaccine candidates in a phase I clinical trial. The results of the clinical trial have been published in "The Journal of Experimental Medicine" (Vol. 205, 63-77).
Currently, the gene sequences are tested in a phase I/II trial by the EuroVacc Foundation. As a licensor, GENEART provides the patented gene sequences (structural design) for these trials.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
Researchers Discover Mutation That Appears to Protect Against Multiple Aspects of Biological AgingNews
The first genetic mutation that appears to protect against multiple aspects of biological aging in humans has been discovered in an extended family of Old Order Amish living in the vicinity of Berne, Indiana, report Northwestern Medicine scientists.READ MORE
Defects in Cell’s ‘Waste Disposal System’ Linked to Parkinson’sNews
An international study has shed new light on the genetic factors associated with Parkinson’s disease, pointing at a group of lysosomal storage disorder genes as potential major contributors to the onset and progression of this common neurodegenerative disorder.READ MORE